There was also evidence for an excess risk of other cancers in aggregate in CHEK2 PTV carriers, although breast and prostate cancer explained more than 50% of the excess cancer risk, and the remaining excess was only statistically significant in males. Here, CHEK2 is linked to prostate carcinoma.